Holen Sie sich die Stockscreener-App
1.05
1.94%
0.02
Handel nachbörslich:
1.04
-0.01
-0.95%
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Will Ocugen Inc. Benefit From Broader Market BounceJuly 2025 Review & High Win Rate Trade Alerts - newsyoung.net
Is Ocugen Inc. part of any ETFMarket Weekly Review & Safe Entry Momentum Stock Tips - newsimpact.co.kr
Can Ocugen Inc. benefit from deglobalization2025 Top Gainers & Verified Swing Trading Watchlists - sundaytimes.kr
Ocugen reports EMA positive advice for acceptability of OCU410ST - MSN
EMA's CHMP Gives Ocugen the Green Light to Submit MAA for OCU410ST Based on GARDian3 Trial - CGTLive®
How to contact the Daily Bulletin - FinancialContent
Ocugen's Strategic Advancements and Financial Positioning Support Buy Rating - AInvest
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen
Acuity Inc. shares rise 1.01% premarket after Ocugen, Inc. receives positive scientific advice. - AInvest
Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy - MarketScreener
Ocugen, Inc. Announces Positive Scientific Advice from the Europ - GuruFocus
Ocugen gets EMA backing for single trial of Stargardt disease therapy - Investing.com Australia
Ocugen, Inc. Announces Positive Scientific Advice from the - GlobeNewswire
Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan - Stock Titan
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Janus Henderson Group Plc shares rise 1.98% after-hours following $20 million investment in Ocugen, Inc. - AInvest
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen raises $20 million in direct offering to Janus Henderson - Investing.com
Ocugen raises $20 million in direct offering to Janus Henderson By Investing.com - Investing.com Australia
Ocugen Secures $20 Million in Registered Direct Offering, Extending Cash Runway into 2026 - AInvest
Ocugen secures crucial $20M funding from Janus Henderson, could unlock additional $30M from warrants - Stock Titan
Ocugen Announces $20M Securities Purchase Agreement to Bolster Gene Therapy Programs - AInvest
Ocugen Announces $20M Securities Purchase Agreement - TipRanks
Ocugen Announces $20 Million Registered Direct Offering of Common Stock and Warrants. - AInvest
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What are the technical indicators suggesting about Ocugen Inc.Free Stock Market Mentorship - Jammu Links News
Is it the right time to buy Ocugen Inc. stockSuperior returns - Jammu Links News
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):